Results 41 to 50 of about 769 (122)

Multisystem Lomentospora prolificans progression on fosmanogepix despite in vitro activity: a call for expanding clinical research on novel antifungals

ASM Case Reports
Lomentospora prolificans is a rare and often fatal cause of invasive mold disease (IMD), particularly in immunocompromised individuals.
R. G. Cooper, Sana Arif, Arthur W. Baker, Nathan P. Wiederhold, Stefanie Sarantopoulos, Mustafa Iftikhar, Kelly Stanly, Brennan Collis, Bin Ni, Beatrice Sim, John R. Perfect, Barbara D. Alexander, Madeleine R. Heldman   +12 more
openalex   +2 more sources

Antifungal treatment strategies and their impact on resistance development in clinical settings. [PDF]

J Antimicrob Chemother
Invasive fungal diseases, particularly among immunocompromised patients, represent a growing clinical challenge due to limited therapeutic options, diagnostic delays and escalating antifungal resistance.
Van Rhijn N, White PL.
europepmc   +2 more sources

Promising antimycotics for the treatment of invasive infections [PDF]

Клиническая микробиология и антимикробная химиотерапия, 2023
This paper provides a review of the largest studies (over the period of 2018 to 2023) of promising novel antimycotics and their possible role in the treatment of invasive mycoses, including infections caused by resistant Candida and Aspergillus isolates.
Ortenberg E.А.
doaj   +1 more source

Efficacy of APX2039 in a Rabbit Model of Cryptococcal Meningitis

mBio, 2022
Cryptococcal Meningitis (CM) is uniformly fatal if not treated, and treatment options are limited. We previously reported on the activity of APX2096, the prodrug of the novel Gwt1 inhibitor APX2039, in a mouse model of CM.
Charles D. Giamberardino, Wiley A. Schell, Jennifer L. Tenor, Dena L. Toffaletti, Julia R. Palmucci, Choiselle Marius, Jane-Valeriane K. Boua, Quinlyn Soltow, Robert Mansbach, M. Arthur Moseley, J. Will Thompson, Laura G. Dubois, William Hope, John R. Perfect, Karen Joy Shaw   +14 more
doaj   +1 more source

Antifungal resistance, combinations and pipeline: oh my!

Drugs in Context, 2023
Invasive fungal infections are a strong contributor to healthcare costs, morbidity and mortality, especially amongst hospitalized patients. Historically, Candida was responsible for approximately 15% of all nosocomial bloodstream infections.
Kayla R Stover, Brandon K Hawkins, J Myles Keck, Katie E Barber, David A Cretella   +4 more
doaj   +1 more source

Calcineurin Inhibitors Synergize with Manogepix to Kill Diverse Human Fungal Pathogens

Journal of Fungi, 2022
Invasive fungal infections have mortality rates of 30–90%, depending on patient co-morbidities and the causative pathogen. The frequent emergence of drug resistance reduces the efficacy of currently approved treatment options, highlighting an urgent need
Sean D. Liston, Luke Whitesell, Mili Kapoor, Karen J. Shaw, Leah E. Cowen   +4 more
doaj   +1 more source

In Vitro Antifungal Activity of Manogepix and Other Antifungal Agents against South African Candida auris Isolates from Bloodstream Infections

Microbiology Spectrum, 2022
We determined the susceptibility of South African Candida auris bloodstream surveillance isolates to manogepix, a novel antifungal, and several registered antifungal agents. C. auris isolates were submitted to a reference laboratory between 2016 and 2017.
Tsidiso G. Maphanga, Ruth S. Mpembe, Serisha D. Naicker, Nelesh P. Govender   +3 more
doaj   +1 more source

Recent Antifungal Pipeline Developments against Candida auris: A Systematic Review

Journal of Fungi, 2022
The alarming spread and impact of multidrug-resistant Candida auris infections alongside the limited therapeutic options have prompted the development of new antifungals.
Rogelio de J. Treviño-Rangel, Gloria M. González, Alexandra M. Montoya, Olga C. Rojas, Mariana Elizondo-Zertuche, Neri A. Álvarez-Villalobos   +5 more
doaj   +1 more source

Antimicrobial activity of manogepix, a first-in-class antifungal, and comparator agents tested against contemporary invasive fungal isolates from an international surveillance programme (2018–2019)

Journal of Global Antimicrobial Resistance, 2021
: Objectives: : Manogepix, the active moiety of the prodrug fosmanogepix, is a novel antifungal with activity against major fungal pathogens including Candida (except Candida krusei), Aspergillus and difficult-to-treat/rare moulds.
Michael A. Pfaller, Michael D. Huband, Robert K. Flamm, Paul A. Bien, Mariana Castanheira   +4 more
doaj   +1 more source

Novel antifungal agents in clinical trials [version 2; peer review: 2 approved]

F1000Research, 2022
Invasive fungal diseases due to resistant yeasts and molds are an important and increasing public health threat, likely due to a growing population of immunosuppressed hosts, increases in antifungal resistance, and improvements in laboratory diagnostics.
Samantha E. Jacobs, Panagiotis Zagaliotis, Thomas J. Walsh   +2 more
doaj   +1 more source